Admedus Limited (ASX:AHZ) non executive chairman Wayne Paterson has acquired 30,000 shares on market at $0.56 per share.
This week Admedus released encouraging interim results from the Phase II clinical study for a Herpes Simplex Virus (HSV-2) therapeutic vaccine which showed a decrease in viral lesions in patients in the trial.
There was a 90% decrease in viral lesions and outbreaks in trial patients, in the monthly rate versus baseline.
No safety issues were noted in this cohort of patients which is the primary endpoint of the Phase II trial.
The company said the data remains blinded and therefore no definitive conclusions can be made but that an analysis of the unblinded data from these 20 study participants will be performed during Q3 2016.
This will include assessment of the immunological endpoints including T cell response, as well as clinical and virological data.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.